| | Variable | pSS () | Probable preclinical pSS () | Nonautoimmune sicca syndrome () |
| | Age, mean (s.d) | 59.6 (11.9) | 58.4 (13.4) | 63.1 (10.1) | | Ocular symptoms, (%) | 25 (100) | 0 (0) | 25 (100) | | Oral symptoms, (%) | 25 (100) | 0 (0) | 25 (100) | | Schirmer I test, ≤5 mm/5 min., (%) | 25 (100) | 0 (0) | 25 (100) | | Unstimulated salivary flow rate, ≤1.5 mL/15 min., (%) | 25 (100) | 0 (0) | 25 (100) | | Salivary secretion, mean (s.d) | 1.0 (0.22) | 2.1 (0.4) | 1.4 (0.17) | | Histopathology, focus score ≥1, (%) | 25 (100) | 20 (80) | 0 (0) | | Salivary gland enlargement, (%) | 5 (20) | 0 (0) | 0 (0) | | Arthralgias, (%) | 18 (72) | 15 (60) | 14 (56) | | Raynaud phenomenon, (%) | 3 (12) | 1 (4) | 0 (0) | | Cutaneous vasculitis, (%) | 1 (4) | 0 (0) | 0 (0) | | Pulmonary involvement, (%) | 3 (12) | 0 (0) | 0 (0) | | Renal involvement, (%) | 0 (0) | 0 (0) | 0 (0) | | Fatigue, (%) | 17 (68) | 19 (76) | 0 (0) | | ESR, , (%) | 7 (28) | 12 (48) | 0 (0) | | Leucopenia, (%) | 6 (24) | 8 (32) | 0 (0) | | Anemia, (%) | 8 (32) | 6 (24) | 0 (0) | | RF, >15 kU/I, (%) | 25 (100) | 25 (100)
| 25 (100) | | ANA, >1 : 40, (%) | 25 (100) | 25 (100) | 25 (100) | | ACA, negative, (%) | 25 (100) | 25 (100) | 25 (100) | | Anti-dsDNA, negative, (%) | 25 (100) | 25 (100)
| 25 (100) | | Anti-Scl-70, negative, (%) | 25 (100) | 25 (100) | 25 (100) | | Anti-Sm, negative, (%) | 25 (100) | 25 (100) | 25 (100) | | Anti-Ro/SSA, (%) | 21(84) | 23 (92) | 0 (0) | | Anti-La/SSB, (%) | 0 (0) | 0 (0) | 0 (0) | | Both anti-Ro/SSA and anti-La/SSB, (%) | 4 (16) | 2 (8) | 0 (0) |
|
|
